title: [Kidney transplantation at the Institute for Clinical and Experimental Medicine].
abstract: BACKGROUND
  Kidney transplantation represents the method of choice of end stage renal disease.
  
  
  RESULTS
  The program of kidney transplantation was established in 1966 in our centre. In recent years, roughly 200 patients have undergone kidney transplantation annually, and 20-30 of them have received a graft from the living donor. Triple immunosuppressive regimen based on tacrolimus, MMF and steroids is given to majority of patients, in a case of high rejection risk; patients have received the induction protocols with polyclonal or monoclonal antilymphocyte globulins. Acute rejection is not a frequent finding in recent years and has occurred in 15% of cases in the first 3 months, the use of induction immunosuppression has decreased the rejection risk. Valgancyclovir has been used as prophylactic agent to prevent and treat cytomegalovirus infection. The usage of this strategy reduced the incidence of CMV infection below 10%. Kidney transplant recipients suffer from similar comorbidities as other renal patients in the long term, as cardiovascular complications, infections and malignancies. Anemia is a frequent complication in patients with graft dysfunction and erythropoesis stimulating agents have been used in its therapy. The median kidney graft survival is 8 years.
  
  
  CONCLUSIONS
  Kidney transplantation is associated with better long-term results when compared with dialysis therapy and thus this method should be offered to all of suitable end stage renal disease patients.
authors.affiliation: Institut klinické a experimentální medicíny Praha, Transplantacní centrum, Klinika nefrologie. ondrej.viklicky@ikem.cz
authors.forename: Ondrej
authors.initials: O
authors.lastname: Viklický
authors.forename: Janka
authors.initials: J
authors.lastname: Slatinská
authors.forename: Marcela
authors.initials: M
authors.lastname: Bürgelová
authors.forename: Stefan
authors.initials: S
authors.lastname: Vítko
authors.forename: Mariana
authors.initials: M
authors.lastname: Urbanová
authors.forename: Renáta
authors.initials: R
authors.lastname: Lazanská
authors.forename: Vladimír
authors.initials: V
authors.lastname: Hanzal
authors.forename: Stepán
authors.initials: S
authors.lastname: Bandúr
authors.forename: Vladimír
authors.initials: V
authors.lastname: Teplan
authors.forename: Ivo
authors.initials: I
authors.lastname: Matl
authors.forename: Libor
authors.initials: L
authors.lastname: Janousek
authors.forename: Eva
authors.initials: E
authors.lastname: Honsová
authors.forename: Monika
authors.initials: M
authors.lastname: Drastichová
authors.forename: Jan
authors.initials: J
authors.lastname: Malý
mesh_terms: D000740:Anemia / Q000209:etiology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000276:immunology; D006084:Graft Rejection; D006801:Humans; D016867:Immunocompromised Host; D016030:Kidney Transplantation / Q000009:adverse effects / Q000706:statistics & numerical data; D008875:Middle Aged